高端吸入制剂开发
Search documents
贝达药业以5000万元投资知兴制药 其专注于高端吸入制剂开发
Zhi Tong Cai Jing· 2026-01-09 14:29
Core Viewpoint - The company has completed the equity transfer with Garden Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical, which specializes in high-end inhalation formulations [1] Group 1: Investment Details - The company invested 50 million yuan to acquire the 2 million yuan registered capital of Zhixing Pharmaceutical [1] - The post-investment ownership in Zhixing Pharmaceutical is 20% [1] Group 2: Company and Product Focus - Zhixing Pharmaceutical focuses on the development of high-end inhalation formulations, with a strong background in core technical personnel and a well-established R&D and production system [1] - Inhalation formulations are defined as drug delivery systems that utilize inhalation devices to administer medication to the respiratory tract, offering local or systemic therapeutic effects [1] Group 3: Market Potential and Applications - Inhalation formulations are recommended by domestic and international guidelines as the preferred treatment for asthma and chronic obstructive pulmonary disease (COPD) [1] - The technology is expanding into other fields, including vaccines and central nervous system applications, and offers new exploration directions for lung cancer treatment due to its targeted delivery and flexibility [1] - The company's investment aligns with its long-term strategic development in the high-end inhalation formulation sector, fostering deep collaboration in innovation and technology platforms [1]
贝达药业(300558.SZ)以5000万元投资知兴制药 其专注于高端吸入制剂开发
智通财经网· 2026-01-09 09:28
Core Viewpoint - The company has completed the equity transfer with Garden Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical, which specializes in high-end inhalation formulations [1] Group 1: Company Investment - The company invested 50 million yuan to acquire the 200 million yuan registered capital of Zhixing Pharmaceutical [1] - This investment aligns with the company's long-term development strategy in the high-end inhalation formulation sector [1] Group 2: Industry Overview - Inhalation formulations are defined as drug delivery systems that utilize inhalation devices to administer medication to the respiratory tract, offering local or systemic therapeutic effects [1] - These formulations are recommended as the preferred treatment method for asthma and chronic obstructive pulmonary disease (COPD) in domestic and international guidelines [1] - Inhalation formulations are expanding into other fields, including vaccines and central nervous system applications, and are being explored for lung cancer treatment due to their targeted delivery and flexibility [1]